Item 8.01. Other Events.
On January 2, 2024, ADC Therapeutics SA (the "Company") received a notice from the New York Stock Exchange ("NYSE") that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE's noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria, as the average closing price of its common shares was below $1.00 over a consecutive 30 trading-day period. As closing price of the common shares on December 29, 2023 and the average closing price of the common shares over the 30 trading-day period ending on December 29, 2023 were both above $1.00, the deficiency was cured.
Attachments
Disclaimer
ADC Therapeutics SA published this content on 04 January 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2024 12:18:06 UTC.